SrasV1, PubMed, Checkpoint, bibRecord, 000986

Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.

Identifieur interne : 000986 ( PubMed/Checkpoint ); précédent : 000985; suivant : 000987

Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.

Auteurs : Xiaoyang Hua ; Rahul Vijay ; Rudragouda Channappanavar ; Jeremiah Athmer ; David K. Meyerholz [États-Unis] ; Nitin Pagedar ; Stephen Tilley [États-Unis] ; Stanley Perlman

Source :

JCI insight [ 2379-3708 ] ; 2018.

RBID : pubmed:29875310

Descripteurs français

KwdFr :
- Activation des macrophages, Administration par voie nasale, Animaux, Femelle, Humains, Immunité innée, Immunité muqueuse, Macrophages (immunologie), Modèles animaux de maladie humaine, Muqueuse nasale (cytologie), Muqueuse nasale (immunologie), Muqueuse nasale (virologie), Pneumopathie virale (), Pneumopathie virale (immunologie), Pneumopathie virale (mortalité), Pneumopathie virale (virologie), Poumon (cytologie), Poumon (immunologie), Poumon (virologie), Souris, Vaccins contre les hépatites virales (administration et posologie), Virus de l'hépatite murine (immunologie), Virus de la grippe A (immunologie), Virus de la grippe A (pathogénicité), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
MESH :
- administration et posologie : Vaccins contre les hépatites virales.
- cytologie : Muqueuse nasale, Poumon.
- immunologie : Macrophages, Muqueuse nasale, Pneumopathie virale, Poumon, Virus de l'hépatite murine, Virus de la grippe A, Virus du SRAS.
- mortalité : Pneumopathie virale.
- pathogénicité : Virus de la grippe A, Virus du SRAS.
- virologie : Muqueuse nasale, Pneumopathie virale, Poumon.
- Activation des macrophages, Administration par voie nasale, Animaux, Femelle, Humains, Immunité innée, Immunité muqueuse, Modèles animaux de maladie humaine, Pneumopathie virale, Souris.

English descriptors

KwdEn :
- Administration, Intranasal, Animals, Disease Models, Animal, Female, Humans, Immunity, Innate, Immunity, Mucosal, Influenza A virus (immunology), Influenza A virus (pathogenicity), Lung (cytology), Lung (immunology), Lung (virology), Macrophage Activation, Macrophages (immunology), Mice, Murine hepatitis virus (immunology), Nasal Mucosa (cytology), Nasal Mucosa (immunology), Nasal Mucosa (virology), Pneumonia, Viral (immunology), Pneumonia, Viral (mortality), Pneumonia, Viral (prevention & control), Pneumonia, Viral (virology), SARS Virus (immunology), SARS Virus (pathogenicity), Viral Hepatitis Vaccines (administration & dosage).
MESH :
- chemical , administration & dosage : Viral Hepatitis Vaccines.
- cytology : Lung, Nasal Mucosa.
- immunology : Influenza A virus, Lung, Macrophages, Murine hepatitis virus, Nasal Mucosa, Pneumonia, Viral, SARS Virus.
- mortality : Pneumonia, Viral.
- pathogenicity : Influenza A virus, SARS Virus.
- prevention & control : Pneumonia, Viral.
- virology : Lung, Nasal Mucosa, Pneumonia, Viral.
- Administration, Intranasal, Animals, Disease Models, Animal, Female, Humans, Immunity, Innate, Immunity, Mucosal, Macrophage Activation, Mice.

Abstract

The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C+ inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C+ inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections.

DOI: 10.1172/jci.insight.99025
PubMed: 29875310

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000998
to stream PubMed, to step Curation: 000998

Links to Exploration step

pubmed:29875310

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.</title>
<author><name sortKey="Hua, Xiaoyang" sort="Hua, Xiaoyang" uniqKey="Hua X" first="Xiaoyang" last="Hua">Xiaoyang Hua</name>
<affiliation><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Otolaryngology-Head and Neck Surgery.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Vijay, Rahul" sort="Vijay, Rahul" uniqKey="Vijay R" first="Rahul" last="Vijay">Rahul Vijay</name>
<affiliation><nlm:affiliation>Interdisciplinary Program in Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">Interdisciplinary Program in Immunology.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Athmer, Jeremiah" sort="Athmer, Jeremiah" uniqKey="Athmer J" first="Jeremiah" last="Athmer">Jeremiah Athmer</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Meyerholz, David K" sort="Meyerholz, David K" uniqKey="Meyerholz D" first="David K" last="Meyerholz">David K. Meyerholz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Pagedar, Nitin" sort="Pagedar, Nitin" uniqKey="Pagedar N" first="Nitin" last="Pagedar">Nitin Pagedar</name>
<affiliation><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Otolaryngology-Head and Neck Surgery.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tilley, Stephen" sort="Tilley, Stephen" uniqKey="Tilley S" first="Stephen" last="Tilley">Stephen Tilley</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
<settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
</affiliation>
</author>
<author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<affiliation><nlm:affiliation>Interdisciplinary Program in Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">Interdisciplinary Program in Immunology.</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29875310</idno>
<idno type="pmid">29875310</idno>
<idno type="doi">10.1172/jci.insight.99025</idno>
<idno type="wicri:Area/PubMed/Corpus">000998</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000998</idno>
<idno type="wicri:Area/PubMed/Curation">000998</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000998</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000986</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000986</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.</title>
<author><name sortKey="Hua, Xiaoyang" sort="Hua, Xiaoyang" uniqKey="Hua X" first="Xiaoyang" last="Hua">Xiaoyang Hua</name>
<affiliation><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Otolaryngology-Head and Neck Surgery.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Vijay, Rahul" sort="Vijay, Rahul" uniqKey="Vijay R" first="Rahul" last="Vijay">Rahul Vijay</name>
<affiliation><nlm:affiliation>Interdisciplinary Program in Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">Interdisciplinary Program in Immunology.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Athmer, Jeremiah" sort="Athmer, Jeremiah" uniqKey="Athmer J" first="Jeremiah" last="Athmer">Jeremiah Athmer</name>
<affiliation><nlm:affiliation>Department of Microbiology and Immunology, and.</nlm:affiliation>
<wicri:noCountry code="subField">and</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Meyerholz, David K" sort="Meyerholz, David K" uniqKey="Meyerholz D" first="David K" last="Meyerholz">David K. Meyerholz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Pagedar, Nitin" sort="Pagedar, Nitin" uniqKey="Pagedar N" first="Nitin" last="Pagedar">Nitin Pagedar</name>
<affiliation><nlm:affiliation>Department of Otolaryngology-Head and Neck Surgery.</nlm:affiliation>
<wicri:noCountry code="no comma">Department of Otolaryngology-Head and Neck Surgery.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Tilley, Stephen" sort="Tilley, Stephen" uniqKey="Tilley S" first="Stephen" last="Tilley">Stephen Tilley</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
<settlement type="city">Chapel Hill (Caroline du Nord)</settlement>
</placeName>
<orgName type="university">Université de Caroline du Nord à Chapel Hill</orgName>
</affiliation>
</author>
<author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<affiliation><nlm:affiliation>Interdisciplinary Program in Immunology.</nlm:affiliation>
<wicri:noCountry code="no comma">Interdisciplinary Program in Immunology.</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">JCI insight</title>
<idno type="eISSN">2379-3708</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Humans</term>
<term>Immunity, Innate</term>
<term>Immunity, Mucosal</term>
<term>Influenza A virus (immunology)</term>
<term>Influenza A virus (pathogenicity)</term>
<term>Lung (cytology)</term>
<term>Lung (immunology)</term>
<term>Lung (virology)</term>
<term>Macrophage Activation</term>
<term>Macrophages (immunology)</term>
<term>Mice</term>
<term>Murine hepatitis virus (immunology)</term>
<term>Nasal Mucosa (cytology)</term>
<term>Nasal Mucosa (immunology)</term>
<term>Nasal Mucosa (virology)</term>
<term>Pneumonia, Viral (immunology)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Pneumonia, Viral (virology)</term>
<term>SARS Virus (immunology)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Viral Hepatitis Vaccines (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Activation des macrophages</term>
<term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunité innée</term>
<term>Immunité muqueuse</term>
<term>Macrophages (immunologie)</term>
<term>Modèles animaux de maladie humaine</term>
<term>Muqueuse nasale (cytologie)</term>
<term>Muqueuse nasale (immunologie)</term>
<term>Muqueuse nasale (virologie)</term>
<term>Pneumopathie virale ()</term>
<term>Pneumopathie virale (immunologie)</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Poumon (cytologie)</term>
<term>Poumon (immunologie)</term>
<term>Poumon (virologie)</term>
<term>Souris</term>
<term>Vaccins contre les hépatites virales (administration et posologie)</term>
<term>Virus de l'hépatite murine (immunologie)</term>
<term>Virus de la grippe A (immunologie)</term>
<term>Virus de la grippe A (pathogénicité)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Hepatitis Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins contre les hépatites virales</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Muqueuse nasale</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Lung</term>
<term>Nasal Mucosa</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Macrophages</term>
<term>Muqueuse nasale</term>
<term>Pneumopathie virale</term>
<term>Poumon</term>
<term>Virus de l'hépatite murine</term>
<term>Virus de la grippe A</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term>
<term>Lung</term>
<term>Macrophages</term>
<term>Murine hepatitis virus</term>
<term>Nasal Mucosa</term>
<term>Pneumonia, Viral</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A virus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus de la grippe A</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Muqueuse nasale</term>
<term>Pneumopathie virale</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
<term>Nasal Mucosa</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Female</term>
<term>Humans</term>
<term>Immunity, Innate</term>
<term>Immunity, Mucosal</term>
<term>Macrophage Activation</term>
<term>Mice</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Activation des macrophages</term>
<term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunité innée</term>
<term>Immunité muqueuse</term>
<term>Modèles animaux de maladie humaine</term>
<term>Pneumopathie virale</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C+ inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C+ inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29875310</PMID>
<DateCompleted><Year>2019</Year>
<Month>10</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2379-3708</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>3</Volume>
<Issue>11</Issue>
<PubDate><Year>2018</Year>
<Month>06</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>JCI insight</Title>
<ISOAbbreviation>JCI Insight</ISOAbbreviation>
</Journal>
<ArticleTitle>Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.</ArticleTitle>
<ELocationID EIdType="doi" ValidYN="Y">10.1172/jci.insight.99025</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">99025</ELocationID>
<Abstract><AbstractText>The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C+ inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C+ inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hua</LastName>
<ForeName>Xiaoyang</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vijay</LastName>
<ForeName>Rahul</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Interdisciplinary Program in Immunology.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Channappanavar</LastName>
<ForeName>Rudragouda</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Athmer</LastName>
<ForeName>Jeremiah</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Meyerholz</LastName>
<ForeName>David K</ForeName>
<Initials>DK</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, University of Iowa, Iowa City, Iowa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pagedar</LastName>
<ForeName>Nitin</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tilley</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perlman</LastName>
<ForeName>Stanley</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Interdisciplinary Program in Immunology.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, and.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P01 AI060699</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 DK054759</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 NS036592</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 DC000040</GrantID>
<Acronym>DC</Acronym>
<Agency>NIDCD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R21 AI096139</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>06</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>JCI Insight</MedlineTA>
<NlmUniqueID>101676073</NlmUniqueID>
<ISSNLinking>2379-3708</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014761">Viral Hepatitis Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009297" MajorTopicYN="N">Nasal Mucosa</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014761" MajorTopicYN="N">Viral Hepatitis Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Immunology</Keyword>
<Keyword MajorTopicYN="Y">Innate immunity</Keyword>
<Keyword MajorTopicYN="Y">Virology</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>12</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>04</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>10</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>6</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29875310</ArticleId>
<ArticleId IdType="pii">99025</ArticleId>
<ArticleId IdType="doi">10.1172/jci.insight.99025</ArticleId>
<ArticleId IdType="pmc">PMC6124400</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):284-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21173243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Oct;88(19):11034-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25056892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Nov;86(21):11416-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22915814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2003 Jun;111(6):1171-83; quiz 1184</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12789212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Biotechnol. 2015 Apr;32:35-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25448230</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2012 Jul;248(1):188-204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22725962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2005 Dec;23(6):649-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16356862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 1997 Mar 28;202(2):123-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9107301</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Pathol. 1997 May;150(5):1735-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9137097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rhinology. 2006 Sep;44(3):179-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17020064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2012 Sep 15;189(6):2702-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22896631</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2015 Feb;89(3):1523-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25428866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2010 Sep 27;207(10):2097-111</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20819925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 1999;54 Suppl 57:94-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10565484</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2006 Feb;6(2):148-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16491139</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2007 Jul;37(7):1739-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17534863</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2008 Dec 22;205(13):3065-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19064696</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5306-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19279209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2013 Oct 10;122(15):2591-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23823318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2014 Mar 27;157(1):121-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24679531</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2005 Jul 15;106(2):593-600</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15827133</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2015 May 4;212(5):699-714</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25897172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2013 Feb 21;38(2):322-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23352232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Aug 15;183(4):2810-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19620305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Host Microbe. 2016 Feb 10;19(2):181-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26867177</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2000 Nov 6;192(9):1317-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11067880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mucosal Immunol. 2015 Mar;8(2):279-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25073677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Mar 1;178(5):3208-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17312169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2014 May 21;5:3864</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24844667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gut. 2016 Apr;65(4):575-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26511795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Apr;83(7):3323-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19144706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Sep;83(18):9258-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19570864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Regul Pept. 2008 Nov 29;151(1-3):35-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18499282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2001 Mar;107(3):469-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11240947</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21402903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Pulm Med. 2005 Jan;11(1):21-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15591884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2014 Feb;24(2):161-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24296781</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2015 Oct 19;212(11):1851-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26392224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Drug Deliv Rev. 2001 Sep 23;51(1-3):21-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11516777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Neurosci. 2013 May;36(5):305-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23384445</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2011 Feb;7(2):e1001304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21383977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mucosal Immunol. 2013 Jan;6(1):45-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22692455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2014 Jun 2;211(6):1037-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24863066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Elife. 2013 Nov 12;2:e01086</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24220507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunol. 2009 Jun;21(3):147-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19223202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2017 Apr 3;214(4):1153-1167</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28264883</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2006 Feb;4(2):121-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16415928</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2012 Oct;80(10):3481-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22851746</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Iowa</li>
</region>
<settlement><li>Chapel Hill (Caroline du Nord)</li>
<li>Iowa City</li>
</settlement>
<orgName><li>Université de Caroline du Nord à Chapel Hill</li>
<li>Université de l'Iowa</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Athmer, Jeremiah" sort="Athmer, Jeremiah" uniqKey="Athmer J" first="Jeremiah" last="Athmer">Jeremiah Athmer</name>
<name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<name sortKey="Hua, Xiaoyang" sort="Hua, Xiaoyang" uniqKey="Hua X" first="Xiaoyang" last="Hua">Xiaoyang Hua</name>
<name sortKey="Pagedar, Nitin" sort="Pagedar, Nitin" uniqKey="Pagedar N" first="Nitin" last="Pagedar">Nitin Pagedar</name>
<name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<name sortKey="Vijay, Rahul" sort="Vijay, Rahul" uniqKey="Vijay R" first="Rahul" last="Vijay">Rahul Vijay</name>
</noCountry>
<country name="États-Unis"><region name="Iowa"><name sortKey="Meyerholz, David K" sort="Meyerholz, David K" uniqKey="Meyerholz D" first="David K" last="Meyerholz">David K. Meyerholz</name>
</region>
<name sortKey="Tilley, Stephen" sort="Tilley, Stephen" uniqKey="Tilley S" first="Stephen" last="Tilley">Stephen Tilley</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000986 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000986 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:29875310
   |texte=   Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:29875310" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.

Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki